Home » Stocks » Abeona Therapeutics

Abeona Therapeutics Inc. (ABEO)

Stock Price: $2.95 USD 0.10 (3.51%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $2.88 -0.07 (-2.37%) Aug 3, 4:45 PM

Stock Price Chart

Key Info

Market Cap 246.91M
Revenue (ttm) 482,000
Net Income (ttm) -105.89M
Shares Out 83.62M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $2.95
Previous Close $2.85
Change ($) 0.10
Change (%) 3.51%
Day's Open 2.86
Day's Range 2.84 - 2.97
Day's Volume 504,277
52-Week Range 1.35 - 5.19

More Stats

Market Cap 246.91M
Enterprise Value 138.58M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 83.62M
Float 69.60M
EPS (basic) -1.65
EPS (diluted) -1.72
FCF / Share -0.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.04M
Short Ratio 2.68
Short % of Float 4.30%
Beta 1.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 512.26
PB Ratio 1.80
Revenue 482,000
Operating Income -106.25M
Net Income -105.89M
Free Cash Flow -66.54M
Net Cash 108.33M
Net Cash / Share 1.29
Gross Margin -10,075.93%
Operating Margin -22,042.95%
Profit Margin n/a
FCF Margin -13,804.15%
ROA -26.87%
ROE -84.65%
ROIC -390.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(219.66% upside)
Current: $2.95
Target: 9.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-258.18%-5.85%-14.52%12.43%-54.7%-53.63%-
Gross Profit-3.000.840.891.040.931.924.14
Operating Income-77.09-58.17-27.84-23.88-18.55-3.13-3.80-4.32
Net Income-76.28-56.67-27.32-21.87-14.53-26.784.45-10.53
Shares Outstanding50.3547.5341.6434.1827.601.940.500.48
Earnings Per Share-1.51-1.19-0.66-0.64-0.53-15.263.04-25.91
Operating Cash Flow-62.82-39.11-22.66-13.01-10.42-1.61--3.96
Capital Expenditures-6.31-9.24-0.86-0.52-0.31---0.01
Free Cash Flow-69.13-48.35-23.52-13.53-10.73-1.61--3.97
Cash & Equivalents12984.9713869.1440.1411.520.420.40
Total Debt7.95----0.40--
Net Cash / Debt12184.9713869.1440.1411.120.420.40
Book Value17813417099.1067.724.82-14.78-17.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Abeona Therapeutics Inc.
Country United States
Employees 88
CEO Joao Siffert

Stock Information

Ticker Symbol ABEO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ABEO
IPO Date September 19, 1980


Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.